IFITM knockout DF1 cells produce higher influenza and newcastle disease viral yields: a proof of concept for avian origin cell-based vaccine production

Vaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry vaccines are currently grown in embryonated chicken eggs (ECE) or egg derived primary cells. These systems can be relatively costly and present a potential...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Vaccine Ročník 61; s. 127360
Hlavní autori:	Samy, Ahmed, Alber, Andreas, Fife, Mark, Hammond, John A.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier Ltd 13.08.2025 Elsevier Limited
Predmet:	Allergy and Immunology Animals Antigens, Differentiation - genetics Avian origin cell line Biohazards Cell culture Cell Line Cell lines Chick Embryo Chickens Cloning CRISPR CRISPR-Cas Systems Disease Egg based vaccine replacement Eggs Epidemics Fibroblasts Fibroblasts - virology Gene editing Gene Knockout Techniques Genes Genome editing Glycoproteins IFITM1 IFITM3 Infections Infectious diseases Infectivity Influenza Influenza A Influenza A virus - growth & development Influenza A virus - immunology Influenza in Birds - immunology Influenza in Birds - prevention & control Influenza Vaccines - immunology Interferon Interferon inducible transmembrane protein Localization Membrane Proteins - genetics Newcastle disease Newcastle Disease - immunology Newcastle Disease - prevention & control Newcastle disease virus - growth & development Newcastle disease virus - immunology Pandemics Poultry Poultry production Proteins Public health RNA-Binding Proteins - genetics Vaccines Viral infections Viral Vaccines - immunology Virus Replication Viruses United Kingdom > UK IFITM3 CRISPR Interferon inducible transmembrane protein Egg based vaccine replacement IFITM1 Avian origin cell line Gene editing
ISSN:	0264-410X, 1873-2518, 1873-2518
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Vaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry vaccines are currently grown in embryonated chicken eggs (ECE) or egg derived primary cells. These systems can be relatively costly and present a potential risk of supply during pandemics when demand for ECE can be high. Furthermore, the scale up of ECE vaccine production can be challenging at short notice, especially when the safe disposal of biohazardous waste is required. Avian-origin immortalised cell lines have the potential to be an ideal surrogate and remove the need to use ECE due to species match. However, the viral yield is often much lower than that of ECE which is at least partly due to the activation of interferon responses. One such response is driven by the interferon-inducible transmembrane proteins (IFITM) that are potent broad range viral restriction factors inhibiting viral cell entry. Using CRISPR/Cas9 we deleted the entire IFITM locus from the immortalised chicken fibroblast cell line DF1 and examined the impact on viral growth. Multiple DF1-IFITM-KO clones confirmed that removing IFITM restriction not only augmented infectivity and viral surface protein expression but significantly increased the viral yield up to 1.5 log10 PFU/ml and 0.8 log10 PFU/ml for influenza A virus (IAV), and Newcastle disease virus (NDV) LaSota strain, respectively. Expression of IFITM3 but not IFITM1 in DF1-IFITM-KO cells restored AIV restriction, while expression of both IFITM1 and IFITM3 restricted NDV infectivity. Together, these data confirm that IFITM proteins significantly reduce viral infectivity and growth in chicken cells and that removing this barrier has the potential to improve cell- based vaccine production. •IFITM knockout in DF1 cells significantly increases viral yields for influenza A and Newcastle disease viruses.•CRISPR/Cas9-mediated deletion of the entire IFITM locus enhances viral infectivity and surface protein expression.•IFITM3 restoration specifically restricts influenza virus, while both IFITM1 and IFITM3 limit Newcastle disease virus.•This study provides proof-of-concept for IFITM-deficient avian cell lines as a potential alternative for vaccine production.•DF1-IFITM-KO cells offer a scalable and cost-effective model for avian-origin vaccine development.
AbstractList	Vaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry vaccines are currently grown in embryonated chicken eggs (ECE) or egg derived primary cells. These systems can be relatively costly and present a potential risk of supply during pandemics when demand for ECE can be high. Furthermore, the scale up of ECE vaccine production can be challenging at short notice, especially when the safe disposal of biohazardous waste is required. Avian-origin immortalised cell lines have the potential to be an ideal surrogate and remove the need to use ECE due to species match. However, the viral yield is often much lower than that of ECE which is at least partly due to the activation of interferon responses. One such response is driven by the interferon-inducible transmembrane proteins (IFITM) that are potent broad range viral restriction factors inhibiting viral cell entry. Using CRISPR/Cas9 we deleted the entire IFITM locus from the immortalised chicken fibroblast cell line DF1 and examined the impact on viral growth. Multiple DF1-IFITM-KO clones confirmed that removing IFITM restriction not only augmented infectivity and viral surface protein expression but significantly increased the viral yield up to 1.5 log PFU/ml and 0.8 log PFU/ml for influenza A virus (IAV), and Newcastle disease virus (NDV) LaSota strain, respectively. Expression of IFITM3 but not IFITM1 in DF1-IFITM-KO cells restored AIV restriction, while expression of both IFITM1 and IFITM3 restricted NDV infectivity. Together, these data confirm that IFITM proteins significantly reduce viral infectivity and growth in chicken cells and that removing this barrier has the potential to improve cell- based vaccine production. AbstractVaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry vaccines are currently grown in embryonated chicken eggs (ECE) or egg derived primary cells. These systems can be relatively costly and present a potential risk of supply during pandemics when demand for ECE can be high. Furthermore, the scale up of ECE vaccine production can be challenging at short notice, especially when the safe disposal of biohazardous waste is required. Avian-origin immortalised cell lines have the potential to be an ideal surrogate and remove the need to use ECE due to species match. However, the viral yield is often much lower than that of ECE which is at least partly due to the activation of interferon responses. One such response is driven by the interferon-inducible transmembrane proteins (IFITM) that are potent broad range viral restriction factors inhibiting viral cell entry. Using CRISPR/Cas9 we deleted the entire IFITM locus from the immortalised chicken fibroblast cell line DF1 and examined the impact on viral growth. Multiple DF1-IFITM-KO clones confirmed that removing IFITM restriction not only augmented infectivity and viral surface protein expression but significantly increased the viral yield up to 1.5 log 10 PFU/ml and 0.8 log 10 PFU/ml for influenza A virus (IAV), and Newcastle disease virus (NDV) LaSota strain, respectively. Expression of IFITM3 but not IFITM1 in DF1-IFITM-KO cells restored AIV restriction, while expression of both IFITM1 and IFITM3 restricted NDV infectivity. Together, these data confirm that IFITM proteins significantly reduce viral infectivity and growth in chicken cells and that removing this barrier has the potential to improve cell- based vaccine production. Vaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry vaccines are currently grown in embryonated chicken eggs (ECE) or egg derived primary cells. These systems can be relatively costly and present a potential risk of supply during pandemics when demand for ECE can be high. Furthermore, the scale up of ECE vaccine production can be challenging at short notice, especially when the safe disposal of biohazardous waste is required. Avian-origin immortalised cell lines have the potential to be an ideal surrogate and remove the need to use ECE due to species match. However, the viral yield is often much lower than that of ECE which is at least partly due to the activation of interferon responses. One such response is driven by the interferon-inducible transmembrane proteins (IFITM) that are potent broad range viral restriction factors inhibiting viral cell entry. Using CRISPR/Cas9 we deleted the entire IFITM locus from the immortalised chicken fibroblast cell line DF1 and examined the impact on viral growth. Multiple DF1-IFITM-KO clones confirmed that removing IFITM restriction not only augmented infectivity and viral surface protein expression but significantly increased the viral yield up to 1.5 log 10 PFU/ml and 0.8 log 10 PFU/ml for influenza A virus (IAV), and Newcastle disease virus (NDV) LaSota strain, respectively. Expression of IFITM3 but not IFITM1 in DF1-IFITM-KO cells restored AIV restriction, while expression of both IFITM1 and IFITM3 restricted NDV infectivity. Together, these data confirm that IFITM proteins significantly reduce viral infectivity and growth in chicken cells and that removing this barrier has the potential to improve cell- based vaccine production. Vaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry vaccines are currently grown in embryonated chicken eggs (ECE) or egg derived primary cells. These systems can be relatively costly and present a potential risk of supply during pandemics when demand for ECE can be high. Furthermore, the scale up of ECE vaccine production can be challenging at short notice, especially when the safe disposal of biohazardous waste is required. Avian-origin immortalised cell lines have the potential to be an ideal surrogate and remove the need to use ECE due to species match. However, the viral yield is often much lower than that of ECE which is at least partly due to the activation of interferon responses. One such response is driven by the interferon-inducible transmembrane proteins (IFITM) that are potent broad range viral restriction factors inhibiting viral cell entry. Using CRISPR/Cas9 we deleted the entire IFITM locus from the immortalised chicken fibroblast cell line DF1 and examined the impact on viral growth. Multiple DF1-IFITM-KO clones confirmed that removing IFITM restriction not only augmented infectivity and viral surface protein expression but significantly increased the viral yield up to 1.5 log10 PFU/ml and 0.8 log10 PFU/ml for influenza A virus (IAV), and Newcastle disease virus (NDV) LaSota strain, respectively. Expression of IFITM3 but not IFITM1 in DF1-IFITM-KO cells restored AIV restriction, while expression of both IFITM1 and IFITM3 restricted NDV infectivity. Together, these data confirm that IFITM proteins significantly reduce viral infectivity and growth in chicken cells and that removing this barrier has the potential to improve cell- based vaccine production. •IFITM knockout in DF1 cells significantly increases viral yields for influenza A and Newcastle disease viruses.•CRISPR/Cas9-mediated deletion of the entire IFITM locus enhances viral infectivity and surface protein expression.•IFITM3 restoration specifically restricts influenza virus, while both IFITM1 and IFITM3 limit Newcastle disease virus.•This study provides proof-of-concept for IFITM-deficient avian cell lines as a potential alternative for vaccine production.•DF1-IFITM-KO cells offer a scalable and cost-effective model for avian-origin vaccine development. Vaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry vaccines are currently grown in embryonated chicken eggs (ECE) or egg derived primary cells. These systems can be relatively costly and present a potential risk of supply during pandemics when demand for ECE can be high. Furthermore, the scale up of ECE vaccine production can be challenging at short notice, especially when the safe disposal of biohazardous waste is required. Avian-origin immortalised cell lines have the potential to be an ideal surrogate and remove the need to use ECE due to species match. However, the viral yield is often much lower than that of ECE which is at least partly due to the activation of interferon responses. One such response is driven by the interferon-inducible transmembrane proteins (IFITM) that are potent broad range viral restriction factors inhibiting viral cell entry. Using CRISPR/Cas9 we deleted the entire IFITM locus from the immortalised chicken fibroblast cell line DF1 and examined the impact on viral growth. Multiple DF1-IFITM-KO clones confirmed that removing IFITM restriction not only augmented infectivity and viral surface protein expression but significantly increased the viral yield up to 1.5 log10 PFU/ml and 0.8 log10 PFU/ml for influenza A virus (IAV), and Newcastle disease virus (NDV) LaSota strain, respectively. Expression of IFITM3 but not IFITM1 in DF1-IFITM-KO cells restored AIV restriction, while expression of both IFITM1 and IFITM3 restricted NDV infectivity. Together, these data confirm that IFITM proteins significantly reduce viral infectivity and growth in chicken cells and that removing this barrier has the potential to improve cell- based vaccine production.Vaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry vaccines are currently grown in embryonated chicken eggs (ECE) or egg derived primary cells. These systems can be relatively costly and present a potential risk of supply during pandemics when demand for ECE can be high. Furthermore, the scale up of ECE vaccine production can be challenging at short notice, especially when the safe disposal of biohazardous waste is required. Avian-origin immortalised cell lines have the potential to be an ideal surrogate and remove the need to use ECE due to species match. However, the viral yield is often much lower than that of ECE which is at least partly due to the activation of interferon responses. One such response is driven by the interferon-inducible transmembrane proteins (IFITM) that are potent broad range viral restriction factors inhibiting viral cell entry. Using CRISPR/Cas9 we deleted the entire IFITM locus from the immortalised chicken fibroblast cell line DF1 and examined the impact on viral growth. Multiple DF1-IFITM-KO clones confirmed that removing IFITM restriction not only augmented infectivity and viral surface protein expression but significantly increased the viral yield up to 1.5 log10 PFU/ml and 0.8 log10 PFU/ml for influenza A virus (IAV), and Newcastle disease virus (NDV) LaSota strain, respectively. Expression of IFITM3 but not IFITM1 in DF1-IFITM-KO cells restored AIV restriction, while expression of both IFITM1 and IFITM3 restricted NDV infectivity. Together, these data confirm that IFITM proteins significantly reduce viral infectivity and growth in chicken cells and that removing this barrier has the potential to improve cell- based vaccine production.
ArticleNumber	127360
Author	Samy, Ahmed Fife, Mark Hammond, John A. Alber, Andreas
Author_xml	– sequence: 1 givenname: Ahmed surname: Samy fullname: Samy, Ahmed email: ahmed.ibrahim@pirbright.ac.uk – sequence: 2 givenname: Andreas surname: Alber fullname: Alber, Andreas – sequence: 3 givenname: Mark surname: Fife fullname: Fife, Mark – sequence: 4 givenname: John A. surname: Hammond fullname: Hammond, John A. email: john.hammond@pirbright.ac.uk
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/40543220$$D View this record in MEDLINE/PubMed
BookMark	eNqNkt-KEzEUxoOsuN3VR1AC3ngzNclM5o-gIqvVwooXruBdSE_O7KadJjWZqdQX8XXN2HEvFkQhEAK_7zvnfCdn5MR5h4Q85mzOGS-fr-d7DWAdzgUTcs5FlZfsHpnxusozIXl9QmZMlEVWcPb1lJzFuGaMyZw3D8hpwWSRC8Fm5Odysbz6SDfOw8YPPX274BSw6yLdBW8GQHpjr28wUOvabkD3Q1PtDHX4HXTsO6TGRtQR6d4G3dGDxc7EF1SPct_SdMA7wF1PWx-o3lvtqA_22rrfZbJV0ho6jTLV7K13D8n9VncRH033OfmyeHd18SG7_PR-efHmMoNCij4roNaiNbJuZAWrSlYCy1brHJhGWBm-QoHpVTBTG1GzBrlhZQElMMOLGnh-Tp4dfVPpbwPGXm1tHDvTDv0QVUpJNGVe8iqhT--gaz8El7pLVCHyqmya0fDJRA2rLRq1C3arw0H9iTwB8ghA8DEGbG8RztS4WrVWUx5qXK06rjbpXh91mOLYWwwqgsWUrbEBoVfG2386vLrjAJ11FnS3wQPG22m4ikIx9Xn8PuPvEZKxUlZjAi__bvAfDfwCPB_ZUw
Cites_doi	10.1128/JVI.02288-20 10.1002/biot.201400387 10.1371/journal.ppat.1006276 10.1038/s41598-017-17730-2 10.1016/j.biologicals.2015.09.002 10.1080/03079457.2016.1138280 10.3389/fvets.2022.936251 10.1371/journal.pone.0160173 10.1038/s41598-022-22885-8 10.1016/j.vaccine.2008.11.066 10.1080/22221751.2023.2172965 10.3390/pr5020020 10.1016/j.vetmic.2022.109597 10.3390/v14061195 10.1099/vir.0.020370-0 10.1146/annurev-virology-031413-085537 10.3390/genes11080918 10.1084/jem.20200303 10.1038/srep23328 10.26508/lsa.201900542 10.1074/jbc.M112.438515 10.1038/s41589-018-0213-2 10.1128/JVI.01443-13 10.1016/j.jmb.2013.09.024 10.1128/JVI.02003-18 10.1128/spectrum.02402-23 10.1128/JVI.00837-21 10.1371/journal.ppat.1007532 10.1128/JVI.01716-18 10.1006/viro.1998.9290 10.1128/JVI.01464-15 10.1128/JVI.01593-15 10.1637/8837-040309-Reg.1 10.1002/jcb.27137 10.1080/03079457.2017.1393044 10.1038/mtna.2015.37 10.1038/s41598-020-74604-w 10.1016/j.puhe.2007.06.005 10.1016/j.cell.2009.12.017 10.1371/journal.ppat.1004048 10.1002/biot.201400388 10.3390/pathogens12040519 10.1016/j.xinn.2022.100357 10.1080/21645515.2024.2373521 10.1128/mBio.03088-19 10.1080/21645515.2015.1016666 10.1099/0022-1317-16-1-95 10.3389/fmicb.2018.03228 10.1016/j.biologicals.2016.01.001 10.1016/j.vaccine.2019.06.005 10.1371/journal.pone.0059307
ContentType	Journal Article
Copyright	2025 Copyright © 2025. Published by Elsevier Ltd. Copyright Elsevier Limited 2025
Copyright_xml	– notice: 2025 – notice: Copyright © 2025. Published by Elsevier Ltd. – notice: Copyright Elsevier Limited 2025
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8
DOI	10.1016/j.vaccine.2025.127360
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE Research Library Prep MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology Public Health
EISSN	1873-2518
EndPage	127360
ExternalDocumentID	40543220 10_1016_j_vaccine_2025_127360 S0264410X25006577 1_s2_0_S0264410X25006577
Genre	Journal Article
GeographicLocations	United Kingdom--UK
GeographicLocations_xml	– name: United Kingdom--UK
GroupedDBID	--- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 5RE 5VS 7-5 71M 7RV 8C1 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACMHX ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT ADSLC AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AEXOQ AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGUBO AGWPP AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BBNVY BENPR BHPHI BKOJK BLXMC BNPGV CJTIS CNWQP CS3 EBS EFJIC EFKBS EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HCIFZ IHE J1W KOM L7B LUGTX LW9 M29 M2O M41 M7P MO0 N9A O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. Q38 ROL RPZ SAB SCC SDF SDG SDP SES SEW SNL SPCBC SSH SSI SSZ T5K UV1 WH7 Z5R ~G- ~HD .GJ 29Q 53G 7X7 88E 8AO 8FE 8FH 8FI 8FJ 8G5 AAQXK ABUWG ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AEUYN AFKRA AGHFR AGQPQ AHHHB AQUVI ASPBG AVWKF AZFZN AZQEC BKEYQ BKNYI BPHCQ BVXVI CCPQU DWQXO EJD FEDTE FGOYB FYUFA G-2 GNUQQ GUQSH HEJ HLV HMCUK HMG HMK HMO HVGLF HX~ HZ~ K9- LK8 M0R M0T M1P NAPCQ PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO R2- SAE SIN SVS UKHRP WOW WUQ XPP ZGI ZXP 9DU AAYXX AFFHD CITATION AGCQF CGR CUY CVF ECM EIF NPM 3V. 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI Q9U 7X8
ID	FETCH-LOGICAL-c452t-4c8a2fd58957cb7572e6faa3c0aecbd1be2ea3c40d8d2809e1d064c6c0d148c13
IEDL.DBID	M7P
ISICitedReferencesCount	0
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001518852000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0264-410X 1873-2518
IngestDate	Sat Nov 01 15:07:26 EDT 2025 Mon Oct 13 06:11:05 EDT 2025 Tue Sep 09 02:32:30 EDT 2025 Sat Nov 29 06:58:11 EST 2025 Sat Sep 20 17:14:16 EDT 2025 Sat Sep 20 19:12:18 EDT 2025 Tue Oct 14 19:38:33 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Keywords	IFITM3 CRISPR Interferon inducible transmembrane protein Egg based vaccine replacement IFITM1 Avian origin cell line Gene editing
Language	English
License	Copyright © 2025. Published by Elsevier Ltd.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c452t-4c8a2fd58957cb7572e6faa3c0aecbd1be2ea3c40d8d2809e1d064c6c0d148c13
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
PMID	40543220
PQID	3242376991
PQPubID	105530
PageCount	1
ParticipantIDs	proquest_miscellaneous_3222963617 proquest_journals_3242376991 pubmed_primary_40543220 crossref_primary_10_1016_j_vaccine_2025_127360 elsevier_sciencedirect_doi_10_1016_j_vaccine_2025_127360 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X25006577 elsevier_clinicalkey_doi_10_1016_j_vaccine_2025_127360
PublicationCentury	2000
PublicationDate	2025-08-13
PublicationDateYYYYMMDD	2025-08-13
PublicationDate_xml	– month: 08 year: 2025 text: 2025-08-13 day: 13
PublicationDecade	2020
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands – name: Kidlington
PublicationTitle	Vaccine
PublicationTitleAlternate	Vaccine
PublicationYear	2025
Publisher	Elsevier Ltd Elsevier Limited
Publisher_xml	– name: Elsevier Ltd – name: Elsevier Limited
References	Himly (bb0180) 1998; 248 Smith (bb0090) 2019; 93 Genzel (bb0230) 2015; 10 Ahi (bb0215) 2020; 11 Rodrigues (bb0055) 2015; 10 van der Sanden (bb0070) 2016; 90 Moresco, Stallknecht, Swayne (bb0175) 2010; 54 Jordan (bb0040) 2009; 27 Blyth (bb0190) 2016; 90 Sato (bb0225) 2016; 6 Shittu (bb0010) 2016; 44 Westermann (bb0150) 2022; 12 Lanz (bb0085) 2021; 218 Poste (bb0210) 1972; 16 Suddala (bb0080) 2019; 15 Adlhoch (bb0015) 2024; 22 Benfield (bb0205) 2020; 3 Meischel (bb0200) 2023; 12 Zhang (bb0145) 2015; 4 Hu (bb0005) 2023; 4 Appourchaux (bb0220) 2019; 93 Hegde (bb0035) 2015; 11 Spence (bb0105) 2019; 15 Perreira (bb0095) 2013; 425 Coronel (bb0045) 2019; 37 Qu (bb0065) 2013; 8 Ravikumar, Chan, Prabakaran (bb0020) 2022; 14 Anafu (bb0245) 2013; 288 Jordan (bb0025) 2016; 45 Chang (bb0135) 2023; 12 Desai (bb0110) 2014; 10 Russier (bb0165) 2017; 13 Kajiwara (bb0170) 2020; 10 Wurm, Wurm (bb0235) 2017; 5 Brass (bb0100) 2009; 139 Staines (bb0265) 2016; 11 Bailey (bb0125) 2014; 1 Zinnecker, Udo, Genzel (bb0050) 2024; 20 Seitz (bb0060) 2010; 91 Zhao (bb0155) 2018; 119 Soubies (bb0250) 2018; 47 Meischel (bb0195) 2021 Smith (bb0115) 2013; 87 Uscher-Pines (bb0030) 2008; 122 Li (bb0130) 2022; 275 Giotis (bb0185) 2017; 7 Steyn (bb0260) 2020; 11 Zhao (bb0120) 2021; 95 Mao (bb0160) 2022; 9 Frye (bb0240) 2016; 44 Zhao (bb0075) 2018; 9 Jadhav (bb0140) 2020 Yang (bb0255) 2024; 12 Desai (10.1016/j.vaccine.2025.127360_bb0110) 2014; 10 Adlhoch (10.1016/j.vaccine.2025.127360_bb0015) 2024; 22 Sato (10.1016/j.vaccine.2025.127360_bb0225) 2016; 6 Benfield (10.1016/j.vaccine.2025.127360_bb0205) 2020; 3 Bailey (10.1016/j.vaccine.2025.127360_bb0125) 2014; 1 Westermann (10.1016/j.vaccine.2025.127360_bb0150) 2022; 12 Meischel (10.1016/j.vaccine.2025.127360_bb0195) 2021; 95 Jadhav (10.1016/j.vaccine.2025.127360_bb0140) 2020 Smith (10.1016/j.vaccine.2025.127360_bb0090) 2019; 93 Jordan (10.1016/j.vaccine.2025.127360_bb0040) 2009; 27 Staines (10.1016/j.vaccine.2025.127360_bb0265) 2016; 11 Zhang (10.1016/j.vaccine.2025.127360_bb0145) 2015; 4 Jordan (10.1016/j.vaccine.2025.127360_bb0025) 2016; 45 Blyth (10.1016/j.vaccine.2025.127360_bb0190) 2016; 90 Shittu (10.1016/j.vaccine.2025.127360_bb0010) 2016; 44 Chang (10.1016/j.vaccine.2025.127360_bb0135) 2023; 12 Appourchaux (10.1016/j.vaccine.2025.127360_bb0220) 2019; 93 Qu (10.1016/j.vaccine.2025.127360_bb0065) 2013; 8 Lanz (10.1016/j.vaccine.2025.127360_bb0085) 2021; 218 Zhao (10.1016/j.vaccine.2025.127360_bb0075) 2018; 9 Russier (10.1016/j.vaccine.2025.127360_bb0165) 2017; 13 Brass (10.1016/j.vaccine.2025.127360_bb0100) 2009; 139 Hu (10.1016/j.vaccine.2025.127360_bb0005) 2023; 4 Zhao (10.1016/j.vaccine.2025.127360_bb0120) 2021; 95 Himly (10.1016/j.vaccine.2025.127360_bb0180) 1998; 248 Seitz (10.1016/j.vaccine.2025.127360_bb0060) 2010; 91 Giotis (10.1016/j.vaccine.2025.127360_bb0185) 2017; 7 Genzel (10.1016/j.vaccine.2025.127360_bb0230) 2015; 10 Zinnecker (10.1016/j.vaccine.2025.127360_bb0050) 2024; 20 Poste (10.1016/j.vaccine.2025.127360_bb0210) 1972; 16 Hegde (10.1016/j.vaccine.2025.127360_bb0035) 2015; 11 Li (10.1016/j.vaccine.2025.127360_bb0130) 2022; 275 Zhao (10.1016/j.vaccine.2025.127360_bb0155) 2018; 119 Frye (10.1016/j.vaccine.2025.127360_bb0240) 2016; 44 Moresco (10.1016/j.vaccine.2025.127360_bb0175) 2010; 54 Coronel (10.1016/j.vaccine.2025.127360_bb0045) 2019; 37 Suddala (10.1016/j.vaccine.2025.127360_bb0080) 2019; 15 van der Sanden (10.1016/j.vaccine.2025.127360_bb0070) 2016; 90 Spence (10.1016/j.vaccine.2025.127360_bb0105) 2019; 15 Kajiwara (10.1016/j.vaccine.2025.127360_bb0170) 2020; 10 Meischel (10.1016/j.vaccine.2025.127360_bb0200) 2023; 12 Ravikumar (10.1016/j.vaccine.2025.127360_bb0020) 2022; 14 Perreira (10.1016/j.vaccine.2025.127360_bb0095) 2013; 425 Ahi (10.1016/j.vaccine.2025.127360_bb0215) 2020; 11 Soubies (10.1016/j.vaccine.2025.127360_bb0250) 2018; 47 Uscher-Pines (10.1016/j.vaccine.2025.127360_bb0030) 2008; 122 Steyn (10.1016/j.vaccine.2025.127360_bb0260) 2020; 11 Wurm (10.1016/j.vaccine.2025.127360_bb0235) 2017; 5 Smith (10.1016/j.vaccine.2025.127360_bb0115) 2013; 87 Yang (10.1016/j.vaccine.2025.127360_bb0255) 2024; 12 Anafu (10.1016/j.vaccine.2025.127360_bb0245) 2013; 288 Mao (10.1016/j.vaccine.2025.127360_bb0160) 2022; 9 Rodrigues (10.1016/j.vaccine.2025.127360_bb0055) 2015; 10
References_xml	– volume: 4 year: 2015 ident: bb0145 article-title: Off-target effects in CRISPR/Cas9-mediated genome engineering publication-title: Molecular Therapy - Nucleic Acids – volume: 6 start-page: 23328 year: 2016 ident: bb0225 article-title: Single-cell lineage tracking analysis reveals that an established cell line comprises putative cancer stem cells and their heterogeneous progeny publication-title: Sci Rep – volume: 90 start-page: 1694 year: 2016 end-page: 1704 ident: bb0070 article-title: Engineering enhanced vaccine cell lines to eradicate vaccine-preventable diseases: the polio end game publication-title: J Virol – volume: 15 year: 2019 ident: bb0080 article-title: Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes publication-title: PLoS Pathog – volume: 93 start-page: e02003 year: 2019 end-page: e02018 ident: bb0090 article-title: Interferon-induced transmembrane protein 1 restricts replication of viruses that enter cells via the plasma membrane publication-title: J Virol – volume: 1 start-page: 261 year: 2014 end-page: 283 ident: bb0125 article-title: IFITM-family proteins: the cell’s first line of antiviral defense publication-title: Annu Rev Virol – volume: 11 year: 2020 ident: bb0260 article-title: The characterization of chIFITMs in avian coronavirus infection in vivo, ex vivo and in vitro publication-title: Genes (Basel) – volume: 44 start-page: 24 year: 2016 end-page: 32 ident: bb0010 article-title: Development, characterization and optimization of a new suspension chicken-induced pluripotent cell line for the production of Newcastle disease vaccine publication-title: Biologicals – volume: 11 year: 2020 ident: bb0215 article-title: IFITM3 reduces retroviral envelope abundance and function and is counteracted by glycoGag publication-title: mBio – volume: 122 start-page: 183 year: 2008 end-page: 191 ident: bb0030 article-title: A systematic analysis of influenza vaccine shortage policies publication-title: Public Health – volume: 27 start-page: 748 year: 2009 end-page: 756 ident: bb0040 article-title: An avian cell line designed for production of highly attenuated viruses publication-title: Vaccine – volume: 275 year: 2022 ident: bb0130 article-title: Chicken interferon-induced transmembrane protein 1 promotes replication of coronavirus infectious bronchitis virus in a cell-specific manner publication-title: Vet Microbiol – volume: 9 start-page: 3228 year: 2018 ident: bb0075 article-title: IFITM genes, variants, and their roles in the control and pathogenesis of viral infections publication-title: Front Microbiol – volume: 54 start-page: 622 year: 2010 end-page: 626 ident: bb0175 article-title: Evaluation and attempted optimization of avian embryos and cell culture methods for efficient isolation and propagation of low pathogenicity avian influenza viruses publication-title: Avian Dis – volume: 37 start-page: 7011 year: 2019 end-page: 7018 ident: bb0045 article-title: Influenza a virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems publication-title: Vaccine – volume: 20 start-page: 2373521 year: 2024 ident: bb0050 article-title: Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations publication-title: Hum Vaccin Immunother – volume: 8 year: 2013 ident: bb0065 article-title: The differential antiviral activities of chicken interferon α (ChIFN-α) and ChIFN-β are related to distinct interferon-stimulated gene expression publication-title: PLoS One – volume: 12 start-page: 519 year: 2023 ident: bb0200 article-title: Caveats of using overexpression approaches to screen cellular host IFITM proteins for antiviral activity publication-title: Pathogens – volume: 10 start-page: 728 year: 2015 end-page: 740 ident: bb0230 article-title: Designing cell lines for viral vaccine production: where do we stand? publication-title: Biotechnol J – volume: 15 start-page: 259 year: 2019 end-page: 268 ident: bb0105 article-title: IFITM3 directly engages and shuttles incoming virus particles to lysosomes publication-title: Nat Chem Biol – volume: 44 start-page: 117 year: 2016 end-page: 122 ident: bb0240 article-title: Industry view on the relative importance of “clonality” of biopharmaceutical-producing cell lines publication-title: Biologicals – volume: 218 year: 2021 ident: bb0085 article-title: IFITM3 incorporation sensitizes influenza a virus to antibody-mediated neutralization publication-title: J Exp Med – volume: 11 year: 2016 ident: bb0265 article-title: A versatile panel of reference gene assays for the measurement of chicken mRNA by quantitative PCR publication-title: PLoS One – volume: 95 year: 2021 ident: bb0120 article-title: Newcastle disease virus entry into chicken macrophages via a pH-dependent, dynamin and Caveola-mediated endocytic pathway that requires Rab5 publication-title: J Virol – volume: 16 start-page: 95 year: 1972 end-page: 97 ident: bb0210 article-title: Cell fusion by Newcastle disease virus publication-title: J Gen Virol – volume: 93 year: 2019 ident: bb0220 article-title: Functional mapping of regions involved in the negative imprinting of Virion particle infectivity and in target cell protection by interferon-induced transmembrane protein 3 against HIV-1 publication-title: J Virol – volume: 139 start-page: 1243 year: 2009 end-page: 1254 ident: bb0100 article-title: The IFITM proteins mediate cellular resistance to influenza a H1N1 virus, West Nile virus, and dengue virus publication-title: Cell – volume: 248 start-page: 295 year: 1998 end-page: 304 ident: bb0180 article-title: The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian Leukosis viruses publication-title: Virology – volume: 47 start-page: 179 year: 2018 end-page: 188 ident: bb0250 article-title: Propagation and titration of infectious bursal disease virus, including non-cell-culture-adapted strains, using ex vivo-stimulated chicken bursal cells publication-title: Avian Pathol – volume: 288 start-page: 17261 year: 2013 end-page: 17271 ident: bb0245 article-title: Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry publication-title: J Biol Chem – volume: 22 year: 2024 ident: bb0015 article-title: Drivers for a pandemic due to avian influenza and options for one health mitigation measures publication-title: EFSA J – volume: 10 start-page: 18008 year: 2020 ident: bb0170 article-title: Cell-penetrating peptide-mediated cell entry of H5N1 highly pathogenic avian influenza virus publication-title: Sci Rep – volume: 7 start-page: 17485 year: 2017 ident: bb0185 article-title: Constitutively elevated levels of SOCS1 suppress innate responses in DF-1 immortalised chicken fibroblast cells publication-title: Sci Rep – volume: 90 start-page: 103 year: 2016 end-page: 116 ident: bb0190 article-title: Duck interferon-inducible transmembrane protein 3 mediates restriction of influenza viruses publication-title: J Virol – volume: 12 start-page: 18211 year: 2022 ident: bb0150 article-title: Wildtype heterogeneity contributes to clonal variability in genome edited cells publication-title: Sci Rep – volume: 5 start-page: 20 year: 2017 ident: bb0235 article-title: Cloning of CHO cells, productivity and genetic stability—a discussion publication-title: Processes – volume: 14 year: 2022 ident: bb0020 article-title: Vaccines against major poultry viral diseases: strategies to improve the breadth and protective efficacy publication-title: Viruses – volume: 119 start-page: 8841 year: 2018 end-page: 8850 ident: bb0155 article-title: The establishment of clonally derived chicken embryonic fibroblast cell line (CSC) with high transfection efficiency and ability as a feeder cell publication-title: J Cell Biochem – year: 2020 ident: bb0140 article-title: Molecular mechanisms of oncolytic properties of Newcastle disease virus (NDV) in human cancer cells – volume: 12 start-page: 2172965 year: 2023 ident: bb0135 article-title: Risk assessment of the newly emerged H7N9 avian influenza viruses publication-title: Emerging Microbes & Infections – volume: 87 start-page: 12957 year: 2013 end-page: 12966 ident: bb0115 article-title: Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro publication-title: J Virol – volume: 3 year: 2020 ident: bb0205 article-title: Bat IFITM3 restriction depends on S-palmitoylation and a polymorphic site within the CD225 domain publication-title: Life Science Alliance – volume: 45 start-page: 137 year: 2016 end-page: 155 ident: bb0025 article-title: Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines publication-title: Avian Pathol – volume: 10 start-page: 1329 year: 2015 end-page: 1344 ident: bb0055 article-title: Viral vaccines and their manufacturing cell substrates: new trends and designs in modern vaccinology publication-title: Biotechnol J – year: 2021 ident: bb0195 article-title: IFITM proteins that restrict the early stages of respiratory virus infection do not influence late-stage replication publication-title: J Virol – volume: 4 year: 2023 ident: bb0005 article-title: Synthetic microbiome for a sustainable poultry industry publication-title: The Innovation – volume: 425 start-page: 4937 year: 2013 end-page: 4955 ident: bb0095 article-title: IFITMs restrict the replication of multiple pathogenic viruses publication-title: J Mol Biol – volume: 12 start-page: e02402 year: 2024 end-page: e02423 ident: bb0255 article-title: Differential analysis of IBV-infected primary chicken embryonic fibroblasts and immortalized DF-1 publication-title: Microbiol Spectrum – volume: 10 year: 2014 ident: bb0110 article-title: IFITM3 restricts influenza a virus entry by blocking the formation of fusion pores following virus-endosome hemifusion publication-title: PLoS Pathog – volume: 13 year: 2017 ident: bb0165 article-title: H1N1 influenza viruses varying widely in hemagglutinin stability transmit efficiently from swine to swine and to ferrets publication-title: PLoS Pathog – volume: 91 start-page: 1754 year: 2010 end-page: 1763 ident: bb0060 article-title: High yields of influenza a virus in Madin-Darby canine kidney cells are promoted by an insufficient interferon-induced antiviral state publication-title: J Gen Virol – volume: 11 start-page: 1223 year: 2015 end-page: 1234 ident: bb0035 article-title: Cell culture-based influenza vaccines: a necessary and indispensable investment for the future publication-title: Hum Vaccin Immunother – volume: 9 year: 2022 ident: bb0160 article-title: Review detection of Newcastle disease virus publication-title: Front Vet Sci – volume: 95 issue: 13 year: 2021 ident: 10.1016/j.vaccine.2025.127360_bb0120 article-title: Newcastle disease virus entry into chicken macrophages via a pH-dependent, dynamin and Caveola-mediated endocytic pathway that requires Rab5 publication-title: J Virol doi: 10.1128/JVI.02288-20 – volume: 10 start-page: 1329 issue: 9 year: 2015 ident: 10.1016/j.vaccine.2025.127360_bb0055 article-title: Viral vaccines and their manufacturing cell substrates: new trends and designs in modern vaccinology publication-title: Biotechnol J doi: 10.1002/biot.201400387 – volume: 13 issue: 3 year: 2017 ident: 10.1016/j.vaccine.2025.127360_bb0165 article-title: H1N1 influenza viruses varying widely in hemagglutinin stability transmit efficiently from swine to swine and to ferrets publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1006276 – volume: 7 start-page: 17485 issue: 1 year: 2017 ident: 10.1016/j.vaccine.2025.127360_bb0185 article-title: Constitutively elevated levels of SOCS1 suppress innate responses in DF-1 immortalised chicken fibroblast cells publication-title: Sci Rep doi: 10.1038/s41598-017-17730-2 – volume: 44 start-page: 24 issue: 1 year: 2016 ident: 10.1016/j.vaccine.2025.127360_bb0010 article-title: Development, characterization and optimization of a new suspension chicken-induced pluripotent cell line for the production of Newcastle disease vaccine publication-title: Biologicals doi: 10.1016/j.biologicals.2015.09.002 – volume: 45 start-page: 137 issue: 2 year: 2016 ident: 10.1016/j.vaccine.2025.127360_bb0025 article-title: Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines publication-title: Avian Pathol doi: 10.1080/03079457.2016.1138280 – volume: 9 year: 2022 ident: 10.1016/j.vaccine.2025.127360_bb0160 article-title: Review detection of Newcastle disease virus publication-title: Front Vet Sci doi: 10.3389/fvets.2022.936251 – volume: 11 issue: 8 year: 2016 ident: 10.1016/j.vaccine.2025.127360_bb0265 article-title: A versatile panel of reference gene assays for the measurement of chicken mRNA by quantitative PCR publication-title: PLoS One doi: 10.1371/journal.pone.0160173 – volume: 12 start-page: 18211 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2025.127360_bb0150 article-title: Wildtype heterogeneity contributes to clonal variability in genome edited cells publication-title: Sci Rep doi: 10.1038/s41598-022-22885-8 – volume: 27 start-page: 748 issue: 5 year: 2009 ident: 10.1016/j.vaccine.2025.127360_bb0040 article-title: An avian cell line designed for production of highly attenuated viruses publication-title: Vaccine doi: 10.1016/j.vaccine.2008.11.066 – volume: 12 start-page: 2172965 issue: 1 year: 2023 ident: 10.1016/j.vaccine.2025.127360_bb0135 article-title: Risk assessment of the newly emerged H7N9 avian influenza viruses publication-title: Emerging Microbes & Infections doi: 10.1080/22221751.2023.2172965 – volume: 5 start-page: 20 issue: 2 year: 2017 ident: 10.1016/j.vaccine.2025.127360_bb0235 article-title: Cloning of CHO cells, productivity and genetic stability—a discussion publication-title: Processes doi: 10.3390/pr5020020 – volume: 275 year: 2022 ident: 10.1016/j.vaccine.2025.127360_bb0130 article-title: Chicken interferon-induced transmembrane protein 1 promotes replication of coronavirus infectious bronchitis virus in a cell-specific manner publication-title: Vet Microbiol doi: 10.1016/j.vetmic.2022.109597 – volume: 14 issue: 6 year: 2022 ident: 10.1016/j.vaccine.2025.127360_bb0020 article-title: Vaccines against major poultry viral diseases: strategies to improve the breadth and protective efficacy publication-title: Viruses doi: 10.3390/v14061195 – volume: 91 start-page: 1754 issue: Pt 7 year: 2010 ident: 10.1016/j.vaccine.2025.127360_bb0060 article-title: High yields of influenza a virus in Madin-Darby canine kidney cells are promoted by an insufficient interferon-induced antiviral state publication-title: J Gen Virol doi: 10.1099/vir.0.020370-0 – volume: 1 start-page: 261 year: 2014 ident: 10.1016/j.vaccine.2025.127360_bb0125 article-title: IFITM-family proteins: the cell’s first line of antiviral defense publication-title: Annu Rev Virol doi: 10.1146/annurev-virology-031413-085537 – volume: 11 issue: 8 year: 2020 ident: 10.1016/j.vaccine.2025.127360_bb0260 article-title: The characterization of chIFITMs in avian coronavirus infection in vivo, ex vivo and in vitro publication-title: Genes (Basel) doi: 10.3390/genes11080918 – volume: 218 issue: 6 year: 2021 ident: 10.1016/j.vaccine.2025.127360_bb0085 article-title: IFITM3 incorporation sensitizes influenza a virus to antibody-mediated neutralization publication-title: J Exp Med doi: 10.1084/jem.20200303 – volume: 6 start-page: 23328 issue: 1 year: 2016 ident: 10.1016/j.vaccine.2025.127360_bb0225 article-title: Single-cell lineage tracking analysis reveals that an established cell line comprises putative cancer stem cells and their heterogeneous progeny publication-title: Sci Rep doi: 10.1038/srep23328 – volume: 3 issue: 1 year: 2020 ident: 10.1016/j.vaccine.2025.127360_bb0205 article-title: Bat IFITM3 restriction depends on S-palmitoylation and a polymorphic site within the CD225 domain publication-title: Life Science Alliance doi: 10.26508/lsa.201900542 – volume: 288 start-page: 17261 issue: 24 year: 2013 ident: 10.1016/j.vaccine.2025.127360_bb0245 article-title: Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry publication-title: J Biol Chem doi: 10.1074/jbc.M112.438515 – volume: 15 start-page: 259 issue: 3 year: 2019 ident: 10.1016/j.vaccine.2025.127360_bb0105 article-title: IFITM3 directly engages and shuttles incoming virus particles to lysosomes publication-title: Nat Chem Biol doi: 10.1038/s41589-018-0213-2 – volume: 87 start-page: 12957 issue: 23 year: 2013 ident: 10.1016/j.vaccine.2025.127360_bb0115 article-title: Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro publication-title: J Virol doi: 10.1128/JVI.01443-13 – volume: 22 issue: 4 year: 2024 ident: 10.1016/j.vaccine.2025.127360_bb0015 article-title: Drivers for a pandemic due to avian influenza and options for one health mitigation measures publication-title: EFSA J – volume: 425 start-page: 4937 issue: 24 year: 2013 ident: 10.1016/j.vaccine.2025.127360_bb0095 article-title: IFITMs restrict the replication of multiple pathogenic viruses publication-title: J Mol Biol doi: 10.1016/j.jmb.2013.09.024 – volume: 93 start-page: e02003 issue: 6 year: 2019 ident: 10.1016/j.vaccine.2025.127360_bb0090 article-title: Interferon-induced transmembrane protein 1 restricts replication of viruses that enter cells via the plasma membrane publication-title: J Virol doi: 10.1128/JVI.02003-18 – year: 2020 ident: 10.1016/j.vaccine.2025.127360_bb0140 – volume: 12 start-page: e02402 issue: 3 year: 2024 ident: 10.1016/j.vaccine.2025.127360_bb0255 article-title: Differential analysis of IBV-infected primary chicken embryonic fibroblasts and immortalized DF-1 publication-title: Microbiol Spectrum doi: 10.1128/spectrum.02402-23 – volume: 95 issue: 20 year: 2021 ident: 10.1016/j.vaccine.2025.127360_bb0195 article-title: IFITM proteins that restrict the early stages of respiratory virus infection do not influence late-stage replication publication-title: J Virol doi: 10.1128/JVI.00837-21 – volume: 15 issue: 1 year: 2019 ident: 10.1016/j.vaccine.2025.127360_bb0080 article-title: Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1007532 – volume: 93 issue: 2 year: 2019 ident: 10.1016/j.vaccine.2025.127360_bb0220 article-title: Functional mapping of regions involved in the negative imprinting of Virion particle infectivity and in target cell protection by interferon-induced transmembrane protein 3 against HIV-1 publication-title: J Virol doi: 10.1128/JVI.01716-18 – volume: 248 start-page: 295 issue: 2 year: 1998 ident: 10.1016/j.vaccine.2025.127360_bb0180 article-title: The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian Leukosis viruses publication-title: Virology doi: 10.1006/viro.1998.9290 – volume: 90 start-page: 1694 issue: 4 year: 2016 ident: 10.1016/j.vaccine.2025.127360_bb0070 article-title: Engineering enhanced vaccine cell lines to eradicate vaccine-preventable diseases: the polio end game publication-title: J Virol doi: 10.1128/JVI.01464-15 – volume: 90 start-page: 103 issue: 1 year: 2016 ident: 10.1016/j.vaccine.2025.127360_bb0190 article-title: Duck interferon-inducible transmembrane protein 3 mediates restriction of influenza viruses publication-title: J Virol doi: 10.1128/JVI.01593-15 – volume: 54 start-page: 622 issue: 1 Suppl year: 2010 ident: 10.1016/j.vaccine.2025.127360_bb0175 article-title: Evaluation and attempted optimization of avian embryos and cell culture methods for efficient isolation and propagation of low pathogenicity avian influenza viruses publication-title: Avian Dis doi: 10.1637/8837-040309-Reg.1 – volume: 119 start-page: 8841 issue: 11 year: 2018 ident: 10.1016/j.vaccine.2025.127360_bb0155 article-title: The establishment of clonally derived chicken embryonic fibroblast cell line (CSC) with high transfection efficiency and ability as a feeder cell publication-title: J Cell Biochem doi: 10.1002/jcb.27137 – volume: 47 start-page: 179 issue: 2 year: 2018 ident: 10.1016/j.vaccine.2025.127360_bb0250 article-title: Propagation and titration of infectious bursal disease virus, including non-cell-culture-adapted strains, using ex vivo-stimulated chicken bursal cells publication-title: Avian Pathol doi: 10.1080/03079457.2017.1393044 – volume: 4 year: 2015 ident: 10.1016/j.vaccine.2025.127360_bb0145 article-title: Off-target effects in CRISPR/Cas9-mediated genome engineering publication-title: Molecular Therapy - Nucleic Acids doi: 10.1038/mtna.2015.37 – volume: 10 start-page: 18008 issue: 1 year: 2020 ident: 10.1016/j.vaccine.2025.127360_bb0170 article-title: Cell-penetrating peptide-mediated cell entry of H5N1 highly pathogenic avian influenza virus publication-title: Sci Rep doi: 10.1038/s41598-020-74604-w – volume: 122 start-page: 183 issue: 2 year: 2008 ident: 10.1016/j.vaccine.2025.127360_bb0030 article-title: A systematic analysis of influenza vaccine shortage policies publication-title: Public Health doi: 10.1016/j.puhe.2007.06.005 – volume: 139 start-page: 1243 issue: 7 year: 2009 ident: 10.1016/j.vaccine.2025.127360_bb0100 article-title: The IFITM proteins mediate cellular resistance to influenza a H1N1 virus, West Nile virus, and dengue virus publication-title: Cell doi: 10.1016/j.cell.2009.12.017 – volume: 10 issue: 4 year: 2014 ident: 10.1016/j.vaccine.2025.127360_bb0110 article-title: IFITM3 restricts influenza a virus entry by blocking the formation of fusion pores following virus-endosome hemifusion publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1004048 – volume: 10 start-page: 728 issue: 5 year: 2015 ident: 10.1016/j.vaccine.2025.127360_bb0230 article-title: Designing cell lines for viral vaccine production: where do we stand? publication-title: Biotechnol J doi: 10.1002/biot.201400388 – volume: 12 start-page: 519 issue: 4 year: 2023 ident: 10.1016/j.vaccine.2025.127360_bb0200 article-title: Caveats of using overexpression approaches to screen cellular host IFITM proteins for antiviral activity publication-title: Pathogens doi: 10.3390/pathogens12040519 – volume: 4 issue: 1 year: 2023 ident: 10.1016/j.vaccine.2025.127360_bb0005 article-title: Synthetic microbiome for a sustainable poultry industry publication-title: The Innovation doi: 10.1016/j.xinn.2022.100357 – volume: 20 start-page: 2373521 issue: 1 year: 2024 ident: 10.1016/j.vaccine.2025.127360_bb0050 article-title: Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2024.2373521 – volume: 11 issue: 1 year: 2020 ident: 10.1016/j.vaccine.2025.127360_bb0215 article-title: IFITM3 reduces retroviral envelope abundance and function and is counteracted by glycoGag publication-title: mBio doi: 10.1128/mBio.03088-19 – volume: 11 start-page: 1223 issue: 5 year: 2015 ident: 10.1016/j.vaccine.2025.127360_bb0035 article-title: Cell culture-based influenza vaccines: a necessary and indispensable investment for the future publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2015.1016666 – volume: 16 start-page: 95 issue: 1 year: 1972 ident: 10.1016/j.vaccine.2025.127360_bb0210 article-title: Cell fusion by Newcastle disease virus publication-title: J Gen Virol doi: 10.1099/0022-1317-16-1-95 – volume: 9 start-page: 3228 year: 2018 ident: 10.1016/j.vaccine.2025.127360_bb0075 article-title: IFITM genes, variants, and their roles in the control and pathogenesis of viral infections publication-title: Front Microbiol doi: 10.3389/fmicb.2018.03228 – volume: 44 start-page: 117 issue: 2 year: 2016 ident: 10.1016/j.vaccine.2025.127360_bb0240 article-title: Industry view on the relative importance of “clonality” of biopharmaceutical-producing cell lines publication-title: Biologicals doi: 10.1016/j.biologicals.2016.01.001 – volume: 37 start-page: 7011 issue: 47 year: 2019 ident: 10.1016/j.vaccine.2025.127360_bb0045 article-title: Influenza a virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems publication-title: Vaccine doi: 10.1016/j.vaccine.2019.06.005 – volume: 8 issue: 3 year: 2013 ident: 10.1016/j.vaccine.2025.127360_bb0065 article-title: The differential antiviral activities of chicken interferon α (ChIFN-α) and ChIFN-β are related to distinct interferon-stimulated gene expression publication-title: PLoS One doi: 10.1371/journal.pone.0059307
SSID	ssj0005319
Score	2.4760077
Snippet	Vaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry vaccines are... AbstractVaccines remain essential for the control of infectious diseases during poultry production, especially in high density systems. Many of poultry...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Publisher
StartPage	127360
SubjectTerms	Allergy and Immunology Animals Antigens, Differentiation - genetics Avian origin cell line Biohazards Cell culture Cell Line Cell lines Chick Embryo Chickens Cloning CRISPR CRISPR-Cas Systems Disease Egg based vaccine replacement Eggs Epidemics Fibroblasts Fibroblasts - virology Gene editing Gene Knockout Techniques Genes Genome editing Glycoproteins IFITM1 IFITM3 Infections Infectious diseases Infectivity Influenza Influenza A Influenza A virus - growth & development Influenza A virus - immunology Influenza in Birds - immunology Influenza in Birds - prevention & control Influenza Vaccines - immunology Interferon Interferon inducible transmembrane protein Localization Membrane Proteins - genetics Newcastle disease Newcastle Disease - immunology Newcastle Disease - prevention & control Newcastle disease virus - growth & development Newcastle disease virus - immunology Pandemics Poultry Poultry production Proteins Public health RNA-Binding Proteins - genetics Vaccines Viral infections Viral Vaccines - immunology Virus Replication Viruses
Title	IFITM knockout DF1 cells produce higher influenza and newcastle disease viral yields: a proof of concept for avian origin cell-based vaccine production
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X25006577 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X25006577 https://dx.doi.org/10.1016/j.vaccine.2025.127360 https://www.ncbi.nlm.nih.gov/pubmed/40543220 https://www.proquest.com/docview/3242376991 https://www.proquest.com/docview/3222963617
Volume	61
WOSCitedRecordID	wos001518852000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIEXJ dateStart: 20211217 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIEXJ dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIEXJ dateStart: 20211208 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M7P dateStart: 20020101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0R dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0T dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1873-2518 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M2O dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9NAEF7RFhAS4ghXoESDhPpUp-vb4QWVkoggEqISKr-t1rtr0YKcUCeRwh_h7zJ7OHkph4QUTZTY413Z45lvdy5CXipJSxWIxBM6fyuSKvTQCFOPi7SMQ0WjkpuS-R_S8TjL897EbbjVLqyy0YlGUcuZ0HvkR8bwpwnCmdfz757uGqW9q66Fxg7Z01USQhO6N9mGeISmsQcuMyIv8mm-zeA5uuiuuNCua1wiBnHXRytuqlReaZt-hz2NDRrc_d_Z3yN3HPqEYysu98k1VbXIDduPct0iN0fO094iBxNb03p9CNNtilZ9CAcw2Va7Rp7bduMPbD5Ti7TOdICNyfKF5nIPyM_hYDgdwdcK1e9suYC3Ax-0z6CGuSk5q-CLCTiBc9s05QcHXkkw7U20IxqcIwl0TPI3WOu4u_oVcM0-KwE_wuZfAoJw4CsUerA9v8wwnjbWEtzDcGNqkXxIPg_605N3nusJ4YkoDhZeJDIelDLOenEqijROA5WUnIeCciUK6RcqUPgrojKTQUZ7ypcIukQiqMSFn_DDR2S3mlXqCYEwyqIy0fVvigKtcoFLdaF4XCQqUb24CNuk20gDm9vSH6yJibtgbsZMiw-z4tMmSSMzrMlrRU3M0Dj9jTG9ilHVTp_UzGd1wCj7RA1-pTkCV8SOadom2YbTQSYLhf5l0P1GVNlmnK2ctsmLzWHUOPpZ8UrNlvqcIEC1jdC3TR7b12FzfxD-R3icPv3zxZ-RW3omem_eD_fJ7uJyqZ6T62K1OK8vO2QnPT3TNE8NzZBmJ36H7B0P-_l7_H7TH09O8d8RtXSqafCxY17_X9kIWtQ
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9NAEB6VckqII1yBAoMEfarT9foMEkKIEjVqElUiRXlb1uu1aEFJqJOg8Ef4F_xGZnft5KUcL31A8otlz661O7PzjecCeK5zVmiuYk-Z_K0w14FHSph5UiVFFGgWFtKWzO8lg0E6GrUPN-BnnQtjwirrM9Ee1PlEmX_ku1bxJzHBmdfTr57pGmW8q3ULDccWB3r5jUy28lV3j_b3Beedd8O3-17VVcBTYcRnXqhSyYs8SttRorIkSriOCykDxaRWWe5nmmu6C1me5jxlbe3npLZVrFhOpoPyAxr3Alw0dfVMCGGfDdchJYFtJEJmTeiFPhutM4Z2T1oLqYyrnExSHrV8Qg22KuaZuvB3WNfqvM7N_221bsGNCl3jGycOt2FDjxtw2fXbXDbgSr-KJGjA9qGr2b3cweE6Ba3cwW08XFfzJprr7scmunytBjQ-mAAim8WM9XB34Ee30x328fOY1MtkPsO9jo_GJ1Li1JbU1fjJBtTgsWsK812iHOdo27cYRztWjjI0MddfcGniCsuXKA35pEC6lMsvRTIyUC5IqNH1NLPTeAaM5FhtfjWnEbm7cHQu630PNseTsX4AGIRpWMSmvk-WEerI0iBRWkZZrGPdjrKgCa2a-8TUlTYRdczfiai-WBh2FY5dmxDXPCrqvF3SNIKU798Ik7MIdVmdl6XwRckFE--ZxedsRMCcsHGSNCFdUVaQ0EG9f5l0qxYNsZpnLRdNeLZ6TCeq2Ss51pO5eYdzUksE7Ztw34nfan3IvAnpOXv458GfwtX9Yb8net3BwSO4Zr7K-CH8YAs2Z6dz_RguqcXsuDx9Yg8QhI_nLYO_AO0HsGU
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9NAEB6VAhUS4ghXoMAgQZ_qZL0-g4QQaoiI2kaRKChvy3q9Fi0oCXUSFP4I_4Vfx-yunfBQjpc-IOUlsmfXWs_xjecCeKpzVmiuYk-Z-q0w14FHRph5UiVFFGgWFtK2zD9IBoN0NOoMN-BHXQtj0iprnWgVdT5R5ht52xr-JCY40y6qtIhht_dy-sUzE6RMpLUep-FYZF8vv5L7Vr7od-ldP-O89_po741XTRjwVBjxmReqVPIij9JOlKgsiRKu40LKQDGpVZb7meaa_oUsT3Oeso72czLhKlYsJzdC-QGtewEuJgFxsalS3_slvSSwQ0XIxQm90GejdfVQ-6S1kMqEzck95VHLJwRhO2SeaRd_h3ut_etd_59P7gZcq1A3vnJichM29LgBl90czmUDtg6rDIMG7AxdL-_lLh6tS9PKXdzB4brLN9FcdR880dVxNaDx3iQW2epmrJe7Bd_7vf7RIX4ak9mZzGfY7floYiUlTm2rXY0fbaINHrthMd8kynGOdqyLCcBjFUBDk4v9GZcm37B8jtKQTwqkn3J1p0jOB8oFCTu6WWd2G8-AlBwrRqj2NKJ4G96dy3nfgc3xZKzvAQZhGhax6fuTZYRGsjRIlJZRFutYd6IsaEKr5kQxdS1PRJ0LeCKqJxaGdYVj3SbENb-Kup6XLJAgo_w3wuQsQl1WerQUvii5YOIts7idjQiwE2ZOkiakK8oKKjoI-C-bbtdiIlb7rGWkCU9Wl0nTmnclx3oyN_dwTuaKIH8T7jpRXJ0PuT0hXWf3_7z4Y9gi0RMH_cH-A7hiHsqEJ_xgGzZnp3P9EC6pxey4PH1kdQnCh_MWwZ-na7jj
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IFITM+knockout+DF1+cells+produce+higher+influenza+and+newcastle+disease+viral+yields%3A+a+proof+of+concept+for+avian+origin+cell-based+vaccine+production&rft.jtitle=Vaccine&rft.au=Samy%2C+Ahmed&rft.au=Alber%2C+Andreas&rft.au=Fife%2C+Mark&rft.au=Hammond%2C+John+A.&rft.date=2025-08-13&rft.issn=0264-410X&rft.volume=61&rft.spage=127360&rft_id=info:doi/10.1016%2Fj.vaccine.2025.127360&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_vaccine_2025_127360
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X25X00165%2Fcov150h.gif